BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase I clinical trial is to test the safety of these CAR T cells in
patients with myeloma.
There are two parts of this study. Part 1 of the study consists of screening for BCMA,
Lenalidomide assignment and cell collection. Part 2 of the study is treatment with modified
CAR T cells.